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ess: lpboulet@med.ulavSummary The magnitude of improvement of respiratory symptoms (RS) and expiratory
flows (EF) following corticosteroid treatment may vary from one asthmatic patient to
another. The distribution of ratio of improvement of the above parameters was assessed in
937 patients with asthma of variable severity who took part in three clinical trials
comparing the effects of chlorofluorocarbon-propelled beclomethasone dipropionate
(CFC-BDP) with similar (n:316) or half-doses (n:581) of extrafine hydrofluoroalkane-
propelled (HFA-BDP) on asthma control. We calculated the ratio of improvement of
shortness of breath, wheezing, sleep disturbance, cough, and chest tightness over the
following physiological parameters: forced expiratory volume in 1 s (FEV1), FEF25/75%,
morning peak expiratory flow, and FVC, from the baseline value to the last set of measures
in the study, while on the study medication. We hypothesized that the ratio of RS/EF
would have a normal distribution and would be higher with extrafine HFA-BDP compared
with CFC-BDP, which has a larger particle size, when FEV1 is used, as it mostly assesses
large airways. Ratios of improvement were normally distributed for both drugs and no
significant shift in its distribution curve was found for HFA-BDP. The ratio of changes in
FEF25/75%/FEV1 was similar in the two groups. In conclusion, the ratio of improvement of
RS/EF is normally distributed over a narrow range, showing a generally good correlation
between improvements in EF and symptoms in asthma; it was, however, similar for the
two BDP molecules tested. This may suggest that this ratio is not useful for evaluating the
effect of corticosteroids on small airways, or that extrafine HFA-BDP acts at the level of
large- to moderate-caliber airways to produce most of its beneficial effect.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Improvements in respiratory symptoms (RS) and
expiratory flows (EF) after inhaled corticosteroid
(ICS) treatment may vary from one asthmatic
patient to another.1 The distribution of these
changes seems to be normal, although the ratio of
improvements in RS over EF has not been evaluated
as such.2 Although they usually seem to change in
parallel, that may not always be the case, as
numerous factors can influence symptoms,
including the intrinsic properties of the ICS and its
site of action, either at the small or large airways
level.3 A predominant effect on small airways could
theoretically influence underlying lung hyperinfla-
tion without affecting measures of large
airway function while contributing to symptom
improvement.
The transition from metered-dose inhalers
(MDI) with chlorofluorocarbons (CFC) to hydrofluor-
oalkanes (HFA) as a propellant to administer
medications such as ICS, following the Montreal
Protocol, has led to the development of drugs
with a smaller mean aerodynamic diameter,
such as the HFA-propelled beclomethasone dipro-
pionate (BDP) marketed under the brand name
QVARTM.4,5 Compared with BDP-CFC, a half-dose of
this drug has comparable or improved efficacy on
asthma control.6–9 Such a reduction of the required
BDP dose to produce the same therapeutic effect
may be due to the increased peripheral lung
penetration of these extrafine aerosol particles,
in addition to increased deposition in large and
intermediate-sized airways, thereby improving the
potential to control peripheral airways inflamma-
tion.10–12 This possibility has been supported by
studies in which high-resolution computed tomo-
graphy showed that HFA-BDP could reduce lung
hyperinflation induced by methacholine inhala-
tion.13
The role of small airway obstruction in the
overall clinical expression of asthma is still
debated.11,12 However, inflammation or remodeling
at this level could possibly influence clinical
features through its influence on lung hyperinfla-
tion. So, the clinical relevance of increased
corticosteroid deposition in the peripheral lung in
asthma remains to be further documented. It is,
however, difficult to assess small airways function
and the effects drugs have on these last. Spiro-
metric indices such as forced expiratory volume
(FEV) between 25% and 75% of forced vital capacity
(FEF25–75%), may provide some information on small
airways function, but this parameter is quite
variable and is also affected by airways of large
caliber.14,15Additional improvements of quality of life scores
have been found with HFA-BDP compared with CFC-
BDP, while there was no difference between the
two drugs in terms of their effect on airway
obstruction, symptom scores or rescue inhaled b2-
agonist use. This suggests that HFA-BDP may have
effects beyond those usually recorded during
clinical trials by current methods of analysis.16
It is possible that in asthmatic subjects, a more
marked symptom reduction when compared with
the degree of improvement in EF measured at the
onset of a forced expiratory maneuver, mostly
influenced by large airways function, reflects an
additional effect of the drug that could be related
to its influence on small airway and/or lung
hyperinflation. It is therefore possible that
there are some subgroups of subjects in whom
improvement in symptoms induced by a therapeu-
tic agent is more important for a given change
in EF, possibly suggesting a predominance of
small airway dysfunction. A simple method of
analyzing this property could be useful to assess
the benefits of drugs with small corticosteroid
particles.
We therefore conducted an analysis of the
relationships between improvements in symptom
scores and EF, first, to look at the distribution of
this ratio in the asthma population and second, as a
potential tool to assess the effect of medications on
small airways. We hypothesized that the ratio
between (1) the improvement in the various
symptom scores, which may be influenced by small
as well as large airways dysfunction and (2) the
change in FEV in 1 s (FEV1), which assesses mostly
airflow limitation in large airways, is normally
distributed, although it is higher with drugs such
as ultrafine HFA-BDP compared with its CFC
counterpart, which has a larger particle size.Methods
Subjects
We analyzed the results obtained in three pre-
viously published clinical trials comparing CFC with
HFA extrafine BDP administered at variable doses,
whose data were graciously provided by 3M
Pharmaceuticals (Table 1).6–8 We performed an
independent analysis of the ratio of improvement
of various RS from the baseline value to the last set
of measures in these studies, in comparison with
the improvement in various physiological para-
meters such as FEV1, morning peak expiratory flow
(PEF), FEF25/75%, and FVC.
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Table 1 Subject’s characteristics for the 3 studies analysed.
Variables Study 16 Study 27 Study 38
HFA-BDP
(n ¼ 157)
CFC-BDP
(n ¼ 166)
HFA-BDP
(n ¼ 354)
CFC-BDP
(n ¼ 79)
HFA-BDP
(n ¼ 70)
CFC-BDP
(n ¼ 71)
Male (%) 52 45 43 34 60 37
Age, years
mean (SD)
— — 39.9 (14.1) 39.8 (14.1) 42.9 (16.0) 39.7 (16.3)
Baseline FEV1
(% predicted)
Dose/dayy Dose/dayy
100 mg: 64.8 100 mg: 65.4
83.3 85.8 82 81400 mg: 66.0 400 mg: 64.4
800 mg: 64.9 800 mg: 66.2
Rounded values.
yOn screening.
L-P. Boulet498The first study was a multicenter, randomized,
parallel-group, double-blind study.6 Asthmatic sub-
jects who had a deterioration in asthma control
after discontinuation of ICS were randomized to
receive one of the six possible treatments: 100,
400, or 800 mg/d of extrafine HFA-BDP or 100, 400,
or 800 mg/d of CFC-BDP for a period of 6 weeks.
Changes in spirometry, daytime asthma symptom
and nighttime asthma-related sleep-disturbance
scores, morning and evening peak EF, and daily
use of inhaled b2-agonist for symptom control on
diary cards were assessed over 6 weeks of treat-
ment.
The second study7 evaluated the long-term
efficacy and safety of switching patients with
asthma on a stable dose of CFC-BDP to therapy
with extrafine HFA-BDP at approximately half of the
previous daily dose of CFC-BDP. This open-label,
randomized, parallel-group trial compared patients
using doses of CFC-BDP from 400 to 1600 mg daily
for a period of 12 months. They were randomized in
a 1–3 ratio of CFC-BDP compared with extrafine
HFA-BDP; a total of 473 patients were randomized,
354 to extrafine HFA-BDP, and 79 to CFC-BDP.
The third study included 141 patients with
moderate to severe asthma randomized to extra-
fine HFA-BDP (n ¼ 70) or CFC-BDP (n ¼ 71) pre-
scribed at respective doses of 800 and 1500 mg daily
for a period of 6 months.8Parameters analyzed
The parameters extracted from the database for
this analysis were first, the symptom scores
recorded during the last 2 weeks of the run-in
period, compared with the last 2 weeks of thestudy, on a scale of 1–5, including: mean shortness-
of-breath score, mean sleep-disturbance score,
mean wheezing score, mean cough score, and
mean chest-tightness score. These were compared
with the following physiological parameters: FEV1,
FEF25–75%, morning PEF, and FVC.
Statistical analysis
All data from the three studies were pooled, as
there were no significant differences among them
in terms of the different analyses. The mean
changes for the different parameters were ex-
pressed as a mean7SEM, and all values were
increased of one1 unit to avoid having to make
calculations with 0 scores, particularly for symp-
toms.
Three types of analyses were done. First, we
looked at the mean percent change in the various
symptom scores during the first 2 weeks of the run-
in and the last 2 weeks of the study; second, we
looked at the mean percent change in the various
physiological parameters for the same time period
as for symptoms; third, we looked to see whether
there were any differences in either the slope or
the pattern of distribution of the ratio between the
percent change in symptoms vs. physiological
parameters for each drug. Analyses were also made
to determine whether there were any differences
in the two first sets of analysis for each parameter.Results
As mentioned above, since our initial evaluation of
the results obtained showed that they were similar
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pooled to perform the analysis.Mean percent change in symptom scores and
expiratory flows
There were no significant differences between the
two drugs in regard to the change in symptom score
during the study except for a slight trend toward a
better improvement in sleep disturbance in favor of
CFC-HFA. There were no significant changes in
regard to FEF25–75% and morning PEF between the
two drugs. There was a slight difference in regard
to the FEV1 in favor of the CFC-HFA. The baseline
FEV1 was slightly higher in the extrafine HFA-BDP
group, and when corrected for baseline values,
there were no more differences between the two
drugs for the mean change in FEV1 over the course
of the studies. The ratio of improvement of
FEF25–75% over FEV1 was not significantly different
between the two molecules (P ¼ 0:44).M
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Figure 1 Comparative improvements (% change) in symptoms
no significant difference was detected. SOB ¼ Shortness of bMean percent change in the ratio of
expiratory flows over symptom scores
Figure 1 expresses the relationship between the
change in the different physiological parameters
and symptom scores for the three main clinical
parameters compared with the three physiological
ones most frequently reported. For all relation-
ships, there were no significant differences in the
slope of the correlation of symptoms over EF
between the two drugs, except for the relationship
between shortness of breath and FEF25–75%, where
the slope for extrafine HFA-BDP was more abrupt,
suggesting a more marked improvement in symp-
toms compared with the improvement in FEF25–75%
for this drug. This, in turn, suggests that for the
same change in FEF25–75%, there was a better
improvement in symptoms with extrafine HFA-BDP.
For CFC-HFA, there was a trend toward a more
abrupt slope in the relationship between mean
sleep disturbance and mean PEF, and in the
relationship between mean sleep disturbance and
mean FEV1.HFA: y = -1.254 + 0.559 x; R2 = 0.082
CFC: y = 0.236 + 0.783 x; R2 = 0.151
2 + 0.195 x; R2 = 0.112
 + 0.216 x; R2 = 0.107
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and expiratory flows after CFC-BDP and HFA-BDP. Overall,
reath; FEF ¼ FEF25/75%.
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L-P. Boulet500The distribution curve of the ratio of shortness of
breath over FEV1 is shown in Fig. 2. There were no
significant differences in the patterns of distribu-
tion of the two drugs, particularly no shift to the
right for HFA-BDP. The overall correlation coeffi-
cients for the ratio of symptoms over EF were
excellent (r40:9), with a narrow range of distribu-
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Figure 2 Distribution curve of the ratio of improvement in
difference was detected. Count ¼ frequency distribution (nDiscussion
The slopes and pattern of distribution of the
relationship (ratio) between the change in RS and
EF in asthmatic subjects treated with similar or
half-doses of extrafine HFA-BDP compared with
CFC-BDP were normally distributed and similar.
This shows how good, in general, the relationship isCo
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t*
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asthma. This ratio, however, examines a dynamic
process of improvement of the respiratory func-
tion; the relationships between symptoms and EF at
rest may be quite different, sometimes showing
marked discrepancies.16 The same comment ap-
plies to the perception of induced bronchoconstric-
tion.17
As FEV1 and PEF measure primarily large- and
medium-sized airways function, if extrafine HFA-
BDP had a predominant effect at the level of the
small airways, with a significant influence on
parameters such as lung hyperinflation, we would
have expected to see a difference between the
slopes of the relationship between the improve-
ment in symptoms and EF in asthmatic subjects.
To support our initial hypothesis, HFA-BDP
seemed to have additional effects compared with
its CFC counterpart. Indeed, Juniper et al.18 found
that there was a better improvement in quality of
life in asthmatic subjects using extrafine HFA-BDP
compared with CFD-BDP, while there were no
significant changes in the other parameters. How-
ever, an improvement in lung hyperinflation could
perhaps explain the improvement in functional
characteristics and symptoms of the subjects on
extrafine HFA-BDP. A previous study showing a
reduction of lung hyperinflation on High-Resolution
Chest Tomography with extrafine HFA-BDP was in
keeping with this possibility that peripheral lung
deposition of HFA-BDP could have resulted in a
reduction in lung hyperinflation.13 However, lung
hyperinflation can also be related to mechanisms
independent of small airway function, such as
persistent contraction of inspiratory muscles.19
Our analysis may suggest that most of the effect
of extrafine HFA-BDP is at the level of large and
medium airways. An increased deposition of drug in
these zones may explain the improved dose/effect,
although it does not exclude the possibility that
there is also an effect at the level of the small
airways that is masked by measurements influenced
by large airway function. If that is the case,
however, it did not seem to contribute significantly
to the change in symptom scores. There is also a
possibility that small airway changes mostly affect
other parameters such as exercise tolerance, or
exercise-induced dynamic lung hyperinflation but
this has to be further studied.
Although we have pooled data from three
different studies, the subanalysis initially showed
that there were no significant differences between
the studies in terms of the ratios of improvements
of the changes in EF and symptom scores. We
therefore considered that it was reasonable to pool
the data for the comparison of these parameters.The ratio of changes should not be affected by the
dosage, as patients were compared for similar
doses and durations of intake, to compare improve-
ments of symptoms over pulmonary function.
We found a very good correlation between the
change in EF and symptoms in this overall group of
subjects. This does not exclude the possibility that
there could be differences in the pattern of
distribution of the relationships (ratio) between
the two, and that one can negate the effects of
another. A subgroup of subjects with a greater
expression of asthma symptoms could have coun-
terbalanced one with a reduced perception of
symptoms for the same degree of EF improvement.
Nevertheless, we found no differences in the
distribution curves of these ratios between the
two drugs tested, and a narrow range of distribu-
tion of the values, suggesting an overall excellent
correlation. Previous distribution curves of the
effects of drugs on various parameters such as EF
have been reported.2 However, to our knowledge,
few data are available on the comparative clinical-
over physiological-parameter changes with bron-
chial anti-inflammatory agents. This could provide
additional information compared with usual mea-
sures if we expect more effects than those on large
airways. In this regard, it would be probably more
revealing in other diseases such as Chronic Pulmon-
ary Obstructive Disease, and this could help to
validate our conceptual model.
The results obtained may, however, be explained
differently. First, it is possible that the patients
tested had minimal or no lung hyperinflation, the
main mechanism that could be involved in a
possible discrepancy between airway function and
symptoms.20 Such hyperinflation could happen
during bronchoconstriction, as during exercise
challenge.21 We have little data, however, on the
prevalence of changes in lung volumes in stable
mild to moderate asthma, while markers of
hyperinflation such as FRC and RV were found to
be increased in exacerbations of asthma or in
severe asthma, conditions differing from the ones
found in our study.22
Second, changes in the ratio of symptoms over
pulmonary function may not be a sensitive means
to detect small airway dysfunction or inflammatory
changes. Previous data had suggested that extra-
fine HFA-BDP does reach the small airways.23 In this
regard, we might have expected to see more
changes in FEF25–75%, or in the ratio of FEF25–75%
over FEV1 with the smaller BDP molecule, since
such markers are considered to reflect small airway
function. This, however, was not the case.
Finally, the choice of parameters to establish the
clinical vs. physiological ratio may not be optimal.
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L-P. Boulet502In many studies, HFA-BDP seemed to influence
mostly symptom-free days. However, we did not
have sufficient data to do this analysis in the
present study.
In conclusion, we found no significant differences
between the slopes of the change in symptom
scores vs. EF in this pooled database coming from
three studies on the comparison between extrafine
HFA and CFC-BDP. This may suggest that most of the
effects of the extrafine HFA-BDP are at the level of
large and medium airways, and that the improved
dosing of extrafine HFA-BDP compared with CFC-
BDP is related to an increased drug deposition at
this level. It may also mean that the analysis of the
RS over measures of large airway function is not
assessing adequately small airways involvement.Acknowledgments
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